Aspira Pathlab & Diagnostics Ltd.BSE: ASPIRA

Financial Result For Half Year Ended 30Th September 2026

· Issued by Aspira Pathlab & Diagnostics Ltd. via BSE India

Filed with BSE · · 10 pages · English

Summary by 6ix AI

The filing includes the authorization for signing these financial results by the Managing Director, Nikunj Velji. Additionally, the document contains a limited review report from the statutory auditor regarding the financial results. The company has also disclosed that there are ongoing legal matters that may impact its financial position, which are noted as contingent liabilities.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/financial-result-for-half-year-ended-30th-september-2026-1

1. The Un-Audited Standalone Financial Results along with Auditor’s Limited Review thereon for the Second Quarter and half yearly ended 30th September 2026. In respect of the above, we hereby enclose the following: ii. Limited Review Report issued by the Statutory Auditor of the Company on the Un-Audited Standalone Financial results for the Second Quarter and half yearly ended 30th September 2026.

Aspira Pathlab & Diagnostics Ltd. on 6ix

Story so far

Earlier from Aspira Pathlab & Diagnostics

Later from Aspira Pathlab & Diagnostics

All Aspira Pathlab & Diagnostics news releases